X-inactivation patch size in human female tissue

confounds the assessment of tumor clonality by Novelli, Marco et al.
X-inactivation patch size in human female tissue
confounds the assessment of tumor clonality
Marco Novelli*†, Antonio Cossu‡, Dahmane Oukrif*, Alberto Quaglia§, Sunil Lakhani¶, Richard Poulsom, Peter Sasieni,
Piera Carta‡, Marcella Contini**, Anna Pasca‡, Giuseppe Palmieri††, Walter Bodmer‡‡, Francesco Tanda**,
and Nick Wright
*Department of Histopathology, Rockefeller Building, University Street, University College London Hospitals, London WC1E 6JJ, United Kingdom; ‡Azienda
USL1, 07100 Sassari, Italy; §Department of Histopathology, Royal Free and University College Medical School, Rowland Hill Street, Hampstead, London
NW3 2PF, United Kingdom; ¶The Breakthrough Toby Robins Breast Cancer Research, Institute of Cancer Research, Fulham Road, London SW3 6JB,
United Kingdom; Cancer Research U.K., P.O. Box 123, Lincoln’s Inn Fields, London WC2A 3PX, United Kingdom; **Institute of Pathology,
University of Sassari, Via Matteotti 58, 07100 Sassari, Italy; ††Institute of Molecular Genetics, Consiglio Nazionale delle Ricerche, Localita`
Tramariglio, 07040 Santa Maria La Palma (Sassari), Italy; and ‡‡Cancer and Immunogenetics Laboratory, Cancer Research U.K.,
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom
Contributed by Walter Bodmer, December 23, 2002
Most models of tumorigenesis assume that tumors are monoclonal
in origin. This conclusion is based largely on studies using X
chromosome-linked markers in females. One important factor,
often ignored in such studies, is the distribution of X-inactivated
cells in tissues. Because lyonization occurs early in development,
many of the progeny of a single embryonic stem cell are grouped
together in the adult, forming patches. As polyclonality can be
demonstrated only at the borders of X-inactivation patches, the
patch size is crucial in determining the chance of demonstrating
polyclonality and hence the number of tumors that need to be
examined to exclude polyclonality. Previously studies using X-
linked genes such as glucose-6-phosphate dehydrogenase have
been handicapped by the need to destroy the tissues to study the
haplotypes of glucose-6-phosphate dehydrogenase [Fialkow, P.-J.
(1976) Biochim. Biophys. Acta 458, 283–321] or to determine the
restriction fragment length polymorphisms of X chromosome-
linked genes [Vogelstein, B., Fearon, E. R., Hamilton, S. R. &
Feinberg, A. P. (1985) Science 227, 642–645]. Here we visualize
X-inactivation patches in human females directly. Results show
that the patch size is relatively large in both the human colon and
breast, confounding assessment of tumor clonality with traditional
X-inactivation studies.
To examine the clonal architecture of normal tissue it isnecessary to have a cellular marker that can be used to
identify a subset of germ-line cells. Experimentally this can be
achieved by using chimeric or mosaic animals. Because of the
process of X inactivation, females heterozygous for X-linked
polymorphisms are functionally mosaic at the mRNA and pro-
tein level. Previous studies have used X-linked genes such as
glucose-6-phosphate dehydrogenase (G6PD) (1) or restriction
fragment length polymorphisms (2) without reference to patch
size. In female mammals the process of X inactivation occurs
early during embryogenesis (day 16 in the human female). This
process involves random inactivation of most of the genes on one
or the other of the two X chromosomes by methylation of CpG
islands (3, 4). The pattern of methylation is stable and inheritable
so that it is passed on to all cellular progeny. The pattern of X
inactivation is also widely believed to be stable during tumori-
genesis (5). As X inactivation occurs at a relatively early stage of
embryogenesis, although there is inevitably some mixing of cells
during further development, in the adult mammal many of the
progeny of a single X-inactivated embryonic cell are arranged
together. In epithelia these groups of cells sharing a common
X-inactivation pattern are termed patches. A single patch may be
formed of the progeny of one cell or several cells all showing the
same X-inactivation pattern. Thus cells in a single patch are
monophenotypic but may be clonal or polyclonal in derivation.
If adjacent cells in the middle of a patch are examined they will
always be monophenotypic. There has been little investigation of
the patch size of X inactivation in normal human female tissues.
Limited data are available from PCR-based microdissection
studies, which show that, in some tissues, the patch size can be
relatively large, some 4 mm in diameter in the human aorta (6).
Materials and Methods
Tissue was collected from surgical resection specimens of Sar-
dinian females heterozygous for the G6PD Mediterranean mu-
tation (563 C 3 T). All patients had been previously shown to
have reduced G6PD enzyme activity, and heterozygosity for the
G6PD Mediterranean mutation was confirmed by PCR analysis
of genomic DNA followed by MBOII restriction endonuclease
digestion. Immediately after surgical resection samples of tissue
were taken from unfixed surgical specimens, snap-frozen in
liquid nitrogen, and stored at 40°C. Normal tissues were
obtained from breast, colonic, small intestinal, and thyroid
resection specimens. Frozen sections (7 m) of the tissues were
mounted on glass slides, air-dried at room temperature for 20
min, and stored at 40°C. Frozen sections were preheated at
53°C for 5 min to inactivate the Mediterranean mutant G6PD (7)
followed by G6PD enzyme histochemistry to demonstrate G6PD
activity (8).
Results
Epithelial cells showed a biphasic staining pattern being either
strongly positive or completely negative for G6PD activity.
Colonic and small intestinal crypts showed a monophenotypic
staining pattern with no evidence of mixed crypts. The epithe-
lium covering small intestinal villi showed a mixed pattern of
staining, similar to that demonstrated in both mouse chimeras
and humans (9), consistent with the fact that the epithelium
covering each villus is derived from multiple crypts (Fig. 1).
Nine samples of normal colonic mucosa were examined from
a single colectomy specimen resected from an 80-year-old female
with colorectal carcinoma. Colonic mucosa was sampled away
from the tumor. There was no history or histological evidence of
inflammatory bowel disease or other colonic pathology. Colonic
crypts stained either entirely positive or entirely negative for
G6PD. A total of 10,538 crypts cut in cross section was examined.
Of those, 50.2% of crypts stained positively (blue) and 49.8%
negatively (white) for G6PD activity. None of 2,260 crypts
examined at patch borders showed a mixed phenotype, confirm-
ing that human colonic crypts are clonal populations. This
finding is consistent with results from previous direct (9) and
indirect studies (10). Crypts were arranged in hexagonal arrays
in large patches, with irregular patch borders, containing up to
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450 individual crypts (Fig. 2). Each crypt was examined in turn,
and the staining pattern of all directly adjacent surrounding
crypts was assessed. This crypt pair analysis showed that 8.2% of
crypt pairs demonstrated a discordant staining pattern, a crypt
pair phenotype index of 8.2% (11).
Multiple samples of breast tissue were examined from lumpec-
tomy specimens from three adult females (aged 55, 82, and 87
years). G6PD staining showed that all 111 small ducts and 57
lobules examined demonstrated a monophenotypic staining
pattern (Fig. 3). Both myoepithelial and luminal ductal cells
always stained in the same fashion. A single large duct showed
large patches of G6PD positivity and negativity. Thyroid tissue
was examined from four patients (age range 41–67 years).
Thyroid parenchyma showed a patchy distribution of staining
with the epithelium of individual follicles showing areas of G6PD
positivity and negativity (Fig. 4). This finding of polyclonal
thyroid follicles is consistent with results from previous animal
studies (12).
Discussion
Evidence supporting the clonal derivation of tumors comes both
directly from clonality studies and indirectly from mutation
analysis. In direct studies of human tumor clonality, early work
focused on tissue derived from black females heterozygous for
the G6PD A variant. These studies examined differences in
electrophoretic patterns of G6PD A and B proteins extracted
from tissue samples (1). Given the admixture of cells constituting
a tumor (tumor cells, vessels, stromal elements, and inflamma-
tory cells), it was not surprising that such tumors were commonly
demonstrated to be polyclonal. More recent studies have used
microdissection and RT-PCR analysis of the X-inactivation
patterns of a variety of genes to examine tumor clonality. PCR
studies typically involve the sampling of multiple small areas of
tumor. Such sampling may miss polyclonality, particularly in
large tumors where expansion of a dominant clone may have
occurred. Furthermore very few of these studies take patch size
into account, which is not surprising given the dearth of infor-
mation available on patch size.
Previous studies of tumor clonality in the human colon have
produced conflicting results: isoenzyme studies of G6PD in
black females showed that a single sporadic colonic carcinoma
(13) and seven colonic adenomas from three patients with
Gardner syndrome were polyclonal (14). Analysis of X-linked
restriction fragment length polymorphisms in microdissected
tissue samples showed 50 human colorectal adenomas of both
familial and sporadic type to be monoclonal (15). In the patient
reported by Novelli et al. (9), who had familial adenomatous
polyposis and was an XOXY sex chimera, 76% of adenomas
Fig. 1. G6PD staining pattern in intestinal crypts. (A) Colonic mucosa stained
for G6PD activity showing longitudinal sections of colonic crypts. In individual
crypts all epithelial cells show a similar staining pattern. (B) Small intestinal
mucosa stained for G6PD activity showing longitudinal sections of crypts and
villi. Epithelial cells in individual crypts show a similar staining pattern but
villous epithelium shows areas of positive and negative staining. (Magnifica-
tions: 90.)
Fig. 2. G6PD staining pattern in colonic patches. Low-power (A) and high-
power (B) views of normal colonic type mucosa stained for G6PD activity with
crypts cut in cross section. Large patches of crypts with irregular patch borders
are seen. (Scale bar: 2 mm.)
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(above monocryptal size) were polyclonal in origin. However, in
this patient, the mean XO patch width was very small (1.24
crypts) and thus the chances of having discordant crypt pairs, and
therefore of finding polyclonal tumors, was high.
Our direct observations here suggest that because of the large
patch size in the colon, X-inactivation studies are heavily biased
toward showing that tumors are monoclonal. With a crypt pair
phenotype index of 8.2%, to exclude the possibility that all adeno-
mas are polyclonal in origin every crypt in at least 43 adenomas
would need to be shown to be monophenotypic (95% confidence
interval). To exclude the possibility that 10% of adenomas are
polyclonal 430 adenomas would need to be examined.
For some time it has been suspected that breast myoepithelial
and epithelial cells share a common clonal origin, based largely
on studies in tissue culture (16, 17). Our studies show, again
directly, that myoepithelial cells and epithelial cells have a
common origin in humans. Lobules in the human breast measure
from 1 to 8 mm in diameter and are drained by a terminal duct,
which leads into the main duct system, the so-called terminal
lobulo-ductular unit. Microarchitectural studies suggest that
tumors arise from the terminal ductularlobular unit (18, 19). In
the human breast, molecular methods have given conflicting
results where X-linked patch size is concerned, with some studies
showing that normal breast tissue was polyclonal in origin, with
a random distribution of X-chromosome inactivation (20) and
others that epithelial patch size is quite large, and that the larger
terminal ductal-lobular units represent the progeny of a single
precursor or stem cell (21). Our studies show directly that this
terminal lobulo-ductular unit often lies all within one patch
clone so that in studies using X inactivation it may be very
difficult ever to demonstrate a polyclonal origin of breast tumors.
Thus, not surprisingly, most studies using such markers report
monoclonality in the early lesions from which breast cancers are
considered to arise, such as intraductal carcinoma and atypical
ductal hyperplasia (22, 23), with only a few studies suggesting a
polyclonal origin (24).
In conclusion, we have demonstrated, directly, the size and
shape of X-linked patch sizes in human tissues. We suggest that
studies in human epithelial neoplasms involving X inactivation
that fail to consider patch size cannot readily answer questions
about tumor clonality. Ideally such studies should involve direct
visualization of tumors and their relationship to patch
boundaries.
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